Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An announcement from Picard Medical, Inc. ( (PMI) ) is now available.
On February 26, 2026, Picard Medical announced that it and its SynCardia subsidiary will participate in the inaugural Hands-On Training Day at the Technology and Heart Failure Therapeutics 2026 conference in Boston on March 1, 2026. The company said the interactive, case-based program will showcase real-world use of the SynCardia Total Artificial Heart and related driver systems in managing advanced heart failure and cardiogenic shock.
The training day will gather leading clinicians and innovators to focus on mechanical circulatory support, hemodynamic monitoring, and complex patient management, with attendees rotating through small-group, interactive stations. Picard framed the event as an extension of its recent SynCardia Training Village in Houston and a key element of its commercial expansion strategy, aimed at deepening clinical partnerships, expanding global awareness, and improving patient outcomes through broader adoption of total artificial heart therapy.
The most recent analyst rating on (PMI) stock is a Hold with a $2.00 price target. To see the full list of analyst forecasts on Picard Medical, Inc. stock, see the PMI Stock Forecast page.
Spark’s Take on PMI Stock
According to Spark, TipRanks’ AI Analyst, PMI is a Neutral.
The score is held down mainly by very weak fundamentals (large ongoing losses and cash burn) and bearish technicals (below key moving averages with negative MACD). Positive corporate updates and financing improve near-term runway and visibility, but do not yet offset the current profitability and cash-flow risks.
To see Spark’s full report on PMI stock, click here.
More about Picard Medical, Inc.
Picard Medical, Inc., listed on the NYSE American, is the parent of Tucson-based SynCardia Systems, which develops, manufactures, and commercializes the SynCardia Total Artificial Heart for patients with end-stage heart failure. The SynCardia device is the first total artificial heart approved by both the U.S. FDA and Health Canada and is currently the only commercially available artificial heart in the United States and Canada, with more than 2,100 implants performed across 27 countries.
SynCardia’s implantable system is designed to assume the full function of a failing or failed human heart and is positioned as the most widely used and extensively studied artificial heart globally. The company focuses on advanced heart failure centers and multidisciplinary clinical teams as key partners in driving adoption of total artificial heart therapy and associated driver systems used to support patients in complex biventricular heart failure cases.
Average Trading Volume: 1,583,698
Technical Sentiment Signal: Strong Sell
For a thorough assessment of PMI stock, go to TipRanks’ Stock Analysis page.